Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?

MLA

Somedeb Ball, et al. “Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?” American Journal of Hematology, vol. 97, Feb. 2022. EBSCOhost, https://doi.org/10.1002/ajh.26504.

APA

Somedeb Ball, Akriti G. Jain, Luis E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, Kendra L. Sweet, Jeffrey E. Lancet, David M. Swoboda, Eric Padron, Rami S. Komrokji, & David A. Sallman. (2022). Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? American Journal of Hematology, 97. https://doi.org/10.1002/ajh.26504

Chicago

Somedeb Ball, Akriti G. Jain, Luis E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, et al. 2022. “Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?” American Journal of Hematology 97 (February). doi:10.1002/ajh.26504.